In the Italian TAM Arimidex (ITA) trial, patients switching to ANA after 2 or more years of TAM were found to have higher levels of lipid metabolism disorders than those continuing on TAM (9.3% vs 4%, respectively) (39). The gene discussed is BTG3; the disease is Disorder of lipid metabolism.